In 2023, Shen et al. confirmed that PRMT5 was able to stimulate chemotherapy-induced neuroendocrine differentiation (NED) in NSCLC, which was an etoposide and cisplatin-resistant malignant phenotype [42]. Here, PRMT5 is linked to non-small cell lung carcinoma.